Literature DB >> 21098714

Melanoma cells express ICOS ligand to promote the activation and expansion of T-regulatory cells.

Natalia Martin-Orozco1, Yufeng Li, Yijun Wang, Shijuan Liu, Patrick Hwu, Yong-Jun Liu, Chen Dong, Laszlo Radvanyi.   

Abstract

CD4(+)CD25(+)Foxp3(+) T-regulatory cells (Tregs) accumulate in tumors; however, little is known about how the tumor environment influences this process. Here we show that human melanomas express inducible T-cell costimulator ligand (ICOS-L/B7H) that can provide costimulation through ICOS for the expansion of activated Tregs maintaining high Foxp3 and CD25 expression as well as a suppressive function. Thus, ICOS-L expression by melanoma tumor cells may directly drive Treg activation and expansion in the tumor microenvironment as another mechanism of immune evasion.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21098714      PMCID: PMC3058814          DOI: 10.1158/0008-5472.CAN-10-1379

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  40 in total

1.  Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines.

Authors:  Gang Zhou; Charles G Drake; Hyam I Levitsky
Journal:  Blood       Date:  2005-09-22       Impact factor: 22.113

Review 2.  Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease.

Authors:  Shimon Sakaguchi; Masahiro Ono; Ruka Setoguchi; Haruhiko Yagi; Shohei Hori; Zoltan Fehervari; Jun Shimizu; Takeshi Takahashi; Takashi Nomura
Journal:  Immunol Rev       Date:  2006-08       Impact factor: 12.988

3.  CD4+CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients.

Authors:  Ashley M Miller; Kajsa Lundberg; Volkan Ozenci; Alison H Banham; Magnus Hellström; Lars Egevad; Pavel Pisa
Journal:  J Immunol       Date:  2006-11-15       Impact factor: 5.422

4.  Tumor-induced expansion of regulatory T cells by conversion of CD4+CD25- lymphocytes is thymus and proliferation independent.

Authors:  Barbara Valzasina; Silvia Piconese; Cristiana Guiducci; Mario P Colombo
Journal:  Cancer Res       Date:  2006-04-15       Impact factor: 12.701

5.  Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell development.

Authors:  Marc A Gavin; Troy R Torgerson; Evan Houston; Paul DeRoos; William Y Ho; Asbjørg Stray-Pedersen; Elizabeth L Ocheltree; Philip D Greenberg; Hans D Ochs; Alexander Y Rudensky
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-14       Impact factor: 11.205

6.  Expression of ICOS on human melanoma-infiltrating CD4+CD25highFoxp3+ T regulatory cells: implications and impact on tumor-mediated immune suppression.

Authors:  Laura Strauss; Christoph Bergmann; Miroslaw J Szczepanski; Stephan Lang; John M Kirkwood; Theresa L Whiteside
Journal:  J Immunol       Date:  2008-03-01       Impact factor: 5.422

7.  Molecular antagonism and plasticity of regulatory and inflammatory T cell programs.

Authors:  Xuexian O Yang; Roza Nurieva; Gustavo J Martinez; Hong Soon Kang; Yeonseok Chung; Bhanu P Pappu; Bhavin Shah; Seon Hee Chang; Kimberly S Schluns; Stephanie S Watowich; Xin-Hua Feng; Anton M Jetten; Chen Dong
Journal:  Immunity       Date:  2008-06-26       Impact factor: 31.745

8.  Circulating tumor antigen-specific regulatory T cells in patients with metastatic melanoma.

Authors:  Luis Vence; A Karolina Palucka; Joseph W Fay; Tomoki Ito; Yong-Jun Liu; Jacques Banchereau; Hideki Ueno
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-18       Impact factor: 11.205

9.  Two functional subsets of FOXP3+ regulatory T cells in human thymus and periphery.

Authors:  Tomoki Ito; Shino Hanabuchi; Yi-Hong Wang; Woong Ryeon Park; Kazuhiko Arima; Laura Bover; F Xiao-Feng Qin; Michel Gilliet; Yong-Jun Liu
Journal:  Immunity       Date:  2008-05-29       Impact factor: 31.745

10.  Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation.

Authors:  François Ghiringhelli; Pierre E Puig; Stephan Roux; Arnaud Parcellier; Elise Schmitt; Eric Solary; Guido Kroemer; François Martin; Bruno Chauffert; Laurence Zitvogel
Journal:  J Exp Med       Date:  2005-09-26       Impact factor: 14.307

View more
  47 in total

Review 1.  Co-stimulatory and co-inhibitory pathways in cancer immunotherapy.

Authors:  Rachel E O'Neill; Xuefang Cao
Journal:  Adv Cancer Res       Date:  2019-04-17       Impact factor: 6.242

2.  ICOSLG-mediated regulatory T-cell expansion and IL-10 production promote progression of glioblastoma.

Authors:  Ryoichi Iwata; Joo Hyoung Lee; Mikio Hayashi; Umberto Dianzani; Kohei Ofune; Masato Maruyama; Souichi Oe; Tomoki Ito; Tetsuo Hashiba; Kunikazu Yoshimura; Masahiro Nonaka; Yosuke Nakano; Lyse Norian; Ichiro Nakano; Akio Asai
Journal:  Neuro Oncol       Date:  2020-03-05       Impact factor: 12.300

3.  Plasmacytoid dendritic cells in melanoma: can we revert bad into good?

Authors:  Jeremy Di Domizio; Olivier Demaria; Michel Gilliet
Journal:  J Invest Dermatol       Date:  2014-07       Impact factor: 8.551

Review 4.  Soluble immune checkpoint molecules: Serum markers for cancer diagnosis and prognosis.

Authors:  Rituparna Chakrabarti; Bhavya Kapse; Gayatri Mukherjee
Journal:  Cancer Rep (Hoboken)       Date:  2019-02-07

5.  Murine regulatory T cells contain hyperproliferative and death-prone subsets with differential ICOS expression.

Authors:  Yong Chen; Shudan Shen; Balachandra K Gorentla; Jimin Gao; Xiao-Ping Zhong
Journal:  J Immunol       Date:  2012-01-09       Impact factor: 5.422

Review 6.  The role of B7 family molecules in hematologic malignancy.

Authors:  Paul Greaves; John G Gribben
Journal:  Blood       Date:  2012-12-06       Impact factor: 22.113

7.  IL-2 therapy promotes suppressive ICOS+ Treg expansion in melanoma patients.

Authors:  Geok Choo Sim; Natalia Martin-Orozco; Lei Jin; Yan Yang; Sheng Wu; Edwina Washington; Deborah Sanders; Carol Lacey; Yijun Wang; Luis Vence; Patrick Hwu; Laszlo Radvanyi
Journal:  J Clin Invest       Date:  2014-01       Impact factor: 14.808

Review 8.  Combination cancer immunotherapy and new immunomodulatory targets.

Authors:  Kathleen M Mahoney; Paul D Rennert; Gordon J Freeman
Journal:  Nat Rev Drug Discov       Date:  2015-08       Impact factor: 84.694

9.  Enhanced inducible costimulator ligand (ICOS-L) expression on dendritic cells in interleukin-10 deficiency and its impact on T-cell subsets in respiratory tract infection.

Authors:  Xiaoling Gao; Lei Zhao; Shuhe Wang; Jie Yang; Xi Yang
Journal:  Mol Med       Date:  2013-11-08       Impact factor: 6.354

10.  Plasmacytoid dendritic cells promote immunosuppression in ovarian cancer via ICOS costimulation of Foxp3(+) T-regulatory cells.

Authors:  Curdin Conrad; Josh Gregorio; Yi-Hong Wang; Tomoki Ito; Stephan Meller; Shino Hanabuchi; Sonya Anderson; Neely Atkinson; Pedro T Ramirez; Yong-Jun Liu; Ralph Freedman; Michel Gilliet
Journal:  Cancer Res       Date:  2012-07-31       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.